share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  09/10 16:29
Moomoo AI 已提取核心訊息
On September 6, 2024, Heart Test Laboratories, Inc., a Texas-based company, entered into a significant financial agreement with Streeterville Capital, LLC, an accredited investor. The agreement involved the issuance of an unsecured promissory note to Heart Test Laboratories for $2,510,000, which includes an original issue discount of $500,000 and $10,000 for transaction expenses. The note carries an 8.5% annual interest rate and is set to mature 18 months post-issuance. Streeterville has the option to redeem up to $270,000 per month starting six months after the note's issuance. If Heart Test Laboratories fails to reduce the note's outstanding balance by at least $900,000 by the 12-month anniversary, the balance will automatically increase by 5%. The company may prepay the balance at any time, subject to the agreement...Show More
On September 6, 2024, Heart Test Laboratories, Inc., a Texas-based company, entered into a significant financial agreement with Streeterville Capital, LLC, an accredited investor. The agreement involved the issuance of an unsecured promissory note to Heart Test Laboratories for $2,510,000, which includes an original issue discount of $500,000 and $10,000 for transaction expenses. The note carries an 8.5% annual interest rate and is set to mature 18 months post-issuance. Streeterville has the option to redeem up to $270,000 per month starting six months after the note's issuance. If Heart Test Laboratories fails to reduce the note's outstanding balance by at least $900,000 by the 12-month anniversary, the balance will automatically increase by 5%. The company may prepay the balance at any time, subject to the agreement's terms. The agreement also includes default provisions that could lead to an automatic increase in the outstanding balance to the lesser of 18% or the maximum rate permitted by law. Heart Test Laboratories has engaged Maxim Group LLC and Ascendiant Capital Markets, LLC as placement agents for the transaction, receiving a commission of 7% of the gross proceeds. The net cash proceeds, amounting to $1,860,000, are intended for general working capital purposes. The full details of the Note Purchase Agreement and the Streeterville Note are included in the company's filings with the SEC.
2024年9月6日,得克薩斯州的心臟檢測實驗室與Streeterville Capital公司,一家合法投資者,達成了一項重要的財務協議。該協議涉及向心髒檢測實驗室發行了一張無抵押的期票,金額爲2,510,000美元,其中包括了50萬美元的原始發行折扣和1萬美元的交易費用。該期票的年利率爲8.5%,在發行後的18個月到期。Streeterville有權在發行後的六個月起每月贖回高達27萬美元的金額。如果心臟檢測實驗室不能在期票發行滿一週年之前將未償餘額至少減少90萬美元,餘額將自動增加5%。公司可隨時根據協議條款提前還清餘額。協議還包括違約條款,可能導致未償餘額增加至18%或法律允許的最高利率...展開全部
2024年9月6日,得克薩斯州的心臟檢測實驗室與Streeterville Capital公司,一家合法投資者,達成了一項重要的財務協議。該協議涉及向心髒檢測實驗室發行了一張無抵押的期票,金額爲2,510,000美元,其中包括了50萬美元的原始發行折扣和1萬美元的交易費用。該期票的年利率爲8.5%,在發行後的18個月到期。Streeterville有權在發行後的六個月起每月贖回高達27萬美元的金額。如果心臟檢測實驗室不能在期票發行滿一週年之前將未償餘額至少減少90萬美元,餘額將自動增加5%。公司可隨時根據協議條款提前還清餘額。協議還包括違約條款,可能導致未償餘額增加至18%或法律允許的最高利率中較小的金額。心臟檢測實驗室聘請了Maxim Group LLC和Ascendiant Capital Markets LLC作爲交易的配售代理商,他們將獲得總收益的7%作爲佣金。淨現金收益爲186萬美元,用於一般經營資金。 完整的《票據購買協議》和Streeterville 期票的細節已經納入公司提交給美國證券交易委員會的文件中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息